Literature DB >> 7665237

Suppression of human melanoma cell growth and metastasis by the melanoma-associated antigen CD63 (ME491).

K J Radford1, J Mallesch, P Hersey.   

Abstract

CD63 has been identified in human melanoma cells by a number of different monoclonal antibodies (MAbs). Studies with MAbs have shown that expression is most marked in naevi and early forms of cutaneous melanoma and reduced in vertical growth phase and metastatic lesions. To investigate further the role of CD63 in progression of melanoma, genomic CD63 was transfected into a CD63-negative human melanoma cell line using an episomal vector. The stable transfected melanoma cells had similar growth rates to control transfected melanoma cells in vitro but much lower growth rates when injected intradermally into athymic nude mice. The CD63-transfected cells also had a reduced number of metastases in the peritoneal cavity and subcutaneous sites when injected intravenously. MAb against CD63 did not influence the growth of CD63-transfected melanoma cells in vitro. Our results confirm previous studies using H-ras-transformed NIH3T3 fibroblasts and suggest that CD63 may have a role as a tumor suppressor gene in human melanoma that acts to limit invasion and progression of melanoma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7665237     DOI: 10.1002/ijc.2910620523

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  22 in total

1.  Palmitoylation of tetraspanin proteins: modulation of CD151 lateral interactions, subcellular distribution, and integrin-dependent cell morphology.

Authors:  Xiuwei Yang; Christoph Claas; Stine-Kathrein Kraeft; Lan Bo Chen; Zemin Wang; Jordan A Kreidberg; Martin E Hemler
Journal:  Mol Biol Cell       Date:  2002-03       Impact factor: 4.138

2.  Selective tetraspan-integrin complexes (CD81/alpha4beta1, CD151/alpha3beta1, CD151/alpha6beta1) under conditions disrupting tetraspan interactions.

Authors:  V Serru; F Le Naour; M Billard; D O Azorsa; F Lanza; C Boucheix; E Rubinstein
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

Review 3.  Tetraspanins and tumor progression.

Authors:  Mekel M Richardson; Lisa K Jennings; Xin A Zhang
Journal:  Clin Exp Metastasis       Date:  2010-12-24       Impact factor: 5.150

4.  Impaired CD19 expression and signaling, enhanced antibody response to type II T independent antigen and reduction of B-1 cells in CD81-deficient mice.

Authors:  E N Tsitsikov; J C Gutierrez-Ramos; R S Geha
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

5.  Tetraspanin CD63 independently predicts poor prognosis in colorectal cancer.

Authors:  Tuomas Kaprio; Jaana Hagström; Leif C Andersson; Caj Haglund
Journal:  Histol Histopathol       Date:  2020-02-19       Impact factor: 2.303

6.  Pattern of expression of tetraspanin antigen genes in Burkitt lymphoma cell lines.

Authors:  M Ferrer; M Yunta; P A Lazo
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

7.  Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients.

Authors:  C I Huang; N Kohno; E Ogawa; M Adachi; T Taki; M Miyake
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

8.  Uroplakin Ib gene transcription in urothelial tumor cells is regulated by CpG methylation.

Authors:  Prue Cowled; Irene Kanter; Lefta Leonardos; Paul Jackson
Journal:  Neoplasia       Date:  2005-12       Impact factor: 5.715

9.  Uroplakin gene expression by normal and neoplastic human urothelium.

Authors:  E D Lobban; B A Smith; G D Hall; P Harnden; P Roberts; P J Selby; L K Trejdosiewicz; J Southgate
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

10.  CD63 tetraspanin is a negative driver of epithelial-to-mesenchymal transition in human melanoma cells.

Authors:  Antonella Lupia; Silvia Peppicelli; Ewa Witort; Francesca Bianchini; Vinicio Carloni; Nicola Pimpinelli; Carmelo Urso; Lorenzo Borgognoni; Sergio Capaccioli; Lido Calorini; Matteo Lulli
Journal:  J Invest Dermatol       Date:  2014-06-18       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.